Generate Biomedicines, Inc. (GENB)
Generate Biomedicines will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Generate Biomedicines Statistics
Total Valuation
| Market Cap | n/a |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 18.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -67.53% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $102,221 |
| Profits Per Employee | -$651,135 |
| Employee Count | 312 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GENB has paid $163,000 in taxes.
| Income Tax | 163,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GENB had revenue of $31.89 million and -$203.15 million in losses.
| Revenue | 31.89M |
| Gross Profit | 31.89M |
| Operating Income | -235.07M |
| Pretax Income | -202.99M |
| Net Income | -203.15M |
| EBITDA | -224.93M |
| EBIT | -235.33M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has $221.84 million in cash and $68.53 million in debt, with a net cash position of $153.31 million.
| Cash & Cash Equivalents | 221.84M |
| Total Debt | 68.53M |
| Net Cash | 153.31M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -615.97M |
| Book Value Per Share | n/a |
| Working Capital | 152.16M |
Cash Flow
In the last 12 months, operating cash flow was -$200.62 million and capital expenditures -$3.51 million, giving a free cash flow of -$204.13 million.
| Operating Cash Flow | -200.62M |
| Capital Expenditures | -3.51M |
| Free Cash Flow | -204.13M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -737.04% and -636.99%.
| Gross Margin | 100.00% |
| Operating Margin | -737.04% |
| Pretax Margin | -636.48% |
| Profit Margin | -636.99% |
| EBITDA Margin | -705.27% |
| EBIT Margin | -737.86% |
| FCF Margin | -640.06% |
Dividends & Yields
GENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |